NCT03672357

Brief Summary

LLR was applied for tumors located at the lower edge and lateral segments of the liver that could be resected more easily than posterosuperior segments. With the development of technology and the growing experience of hepatobiliary surgeons, LLR has been expanded to major liver resections, anatomical resections, and donor hepatectomies by skilled surgeons. However, due to the concerns over the risk of operative bleeding, tumor seeding and positive resection margin, the true benefit of LLR remains unclear across surgical community.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
80

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Jan 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 19, 2018

Completed
26 days until next milestone

First Posted

Study publicly available on registry

September 14, 2018

Completed
4 months until next milestone

Study Start

First participant enrolled

January 1, 2019

Completed
5.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2024

Completed
7 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2025

Completed
Last Updated

December 13, 2018

Status Verified

December 1, 2018

Enrollment Period

5.7 years

First QC Date

August 19, 2018

Last Update Submit

December 12, 2018

Conditions

Keywords

Liver resectionLaparoscopic surgeryfast recovery

Outcome Measures

Primary Outcomes (2)

  • Change of serum glutamic oxalacetic transaminase

    Change of serum glutamic oxalacetic transaminase after liver resection.These values will be recorded preoperative, and postoperative day-1,3,5,7.

    up to 7 days after liver resection

  • Change of serum glutamic-pyruvic transaminase

    Change of serum glutamic-pyruvic transaminase after liver resection.These values will be recorded preoperative, and postoperative day-1,3,5,7.

    up to 7 days after liver resection

Secondary Outcomes (17)

  • Postoperative complication(Rates in different grades)

    up to 30 days after liver resection

  • Mortality rates

    up to 30 days after liver resection

  • Hospital duration after operation (days)

    up to 30 days after liver resection

  • Operation time(min)

    up to 30 days after liver resection

  • Blood loss(ml)

    up to 30 days after liver resection

  • +12 more secondary outcomes

Study Arms (2)

Laparoscopic liver resection

EXPERIMENTAL

Laparoscopic hepatectomy

Procedure: Laparoscopic liver resection

Open liver resection

OTHER

Open hepatectomy

Procedure: Open liver resection

Interventions

Laparoscopic hepatectomy

Laparoscopic liver resection

Traditional open hepatectomy

Open liver resection

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient who underwent hepatectomy for benign or malignant neoplasm of the liver, and is suitable for both open and laparoscopic liver resection;
  • Child-Pugh A without portal hypertension
  • No portosystemic shunt
  • No previous abdominal operation history.
  • American society of anesthesiology class(ASA): I or II
  • Age 18 to 80

You may not qualify if:

  • Additional intervention to the liver (Radio Frequent Ablation, Percutaneous Ethanol. Injection Therapy or others)
  • Combined hepatectomy
  • Intrahepatic duct stone disease
  • Liver disease caused splenomegaly
  • Previous hepatectomy
  • Combined operation for extrahepatic disease
  • Vulnerable population (mental retardation, pregnancy)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The second hospital of Anhui Medical University,

Hefei, Anhui, 230061, China

Location

Central Study Contacts

dachen zhou, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Director of the hepatobiliary surgery department

Study Record Dates

First Submitted

August 19, 2018

First Posted

September 14, 2018

Study Start

January 1, 2019

Primary Completion

September 1, 2024

Study Completion

April 1, 2025

Last Updated

December 13, 2018

Record last verified: 2018-12

Data Sharing

IPD Sharing
Will not share

Locations